This study aimed to validate a model for predicting breakthrough FN in patients receiving G-CSF prophylaxis for their first cycle of chemotherapy based on pre-therapy risk factors in consecutive treatment-naive patients with lymphoma. Here, CSF3 is linked to lymphoma.